See the DrugPatentWatch profile for Vyndaqel
What “orphan market exclusivity” applies to Vyndaqel?
Vyndaqel (tafamidis) is an orphan drug. In the U.S., “orphan market exclusivity” refers to the period during which the FDA generally will not approve another drug for the same orphan indication, unless an exception applies (for example, if the sponsor does not maintain the drug’s orphan approval, or if a later product is clinically superior). The exclusivity period is typically 7 years for orphan drugs.
How long is orphan market exclusivity for Vyndaqel?
The exclusivity length for orphan drugs in the U.S. is 7 years. (That is the standard duration of U.S. orphan drug market exclusivity under the Orphan Drug Act.) The exact start and end dates for Vyndaqel depend on the specific FDA approval(s) that received orphan designation/approval for each indication and the approval date of the drug for that indication.
When does exclusivity end?
The end date depends on which Vyndaqel approval is being considered (and whether there were separate approvals tied to different indications). If you tell me the indication you mean (for example, a specific transthyretin amyloid cardiomyopathy labeling segment) and the country (U.S. vs. EU), I can narrow it to the relevant exclusivity window.
Does Vyndaqel have exclusivity that blocks all competition?
Not necessarily. Orphan market exclusivity blocks approval of the same drug for the same orphan indication, but it does not always prevent:
- approvals for different indications,
- approvals for different formulations/uses that are outside the protected indication, or
- approvals that meet an FDA exception (including clinical superiority in some circumstances).
How do updates to labeling or additional indications affect exclusivity?
Later FDA actions (such as supplemental approvals tied to additional indications) can create new orphan exclusivity events, or they can be eligible for different regulatory pathways than the original orphan indication. That means a drug can face multiple exclusivity clocks tied to different approvals, rather than a single uniform date.
What about Europe—does “orphan market exclusivity” mean the same thing?
No. The EU has different orphan-related rules and time limits (including concepts like market exclusivity and how they interact with later approvals). If your question is specifically about “orphan market exclusivity” in Europe, the timeline can differ from the U.S. 7-year framework.
Who typically challenges orphan exclusivity, and what would that look like?
In practice, competitors (including generic makers or other sponsored drugs) usually focus on whether:
- the later product targets the same orphan indication,
- the sponsor maintained orphan status and met ongoing requirements, and
- an FDA exception applies (for example, clinical superiority).
What I need to give you exact dates
To answer with precise “from/to” dates for Vyndaqel exclusivity, I need:
1) the country (U.S. or EU), and
2) the specific indication wording you mean (the exact label/orphan indication).
If you share those two details, I can pinpoint the exclusivity end date tied to that specific orphan approval.